Skip to main content
Caplight Logo









Poietis

Poietis

Private
PessacHealthcare & Life Scienceshttps://www.poietis.com/

Last Round

Series A

Mar 27, 2018

Total Funding Raised

$11.98M

Company Overview

Poietis is a biotechnology company that develops and produces human tissues using 4D laser-assisted bioprinting for pharmaceutical, cosmetic, and regenerative medicine applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, 3D Printing, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts, Hardware + Subscription

AI Layer

Application

Keywords

4D bioprintinglaser-assisted bioprintingtissue engineeringhuman tissue modelsbioprinting platformbiofabricationalternatives to animal testingregenerative medicinebioprinted skindrug discoveryin vitro models3D cell culturecosmetic testingmultimodal bioprinterAI-guided bioprinting

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Poietis Comparables

Compare Poietis with similar companies based on industry and business-model similarity.

Poietis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Brinter
85%
Regemat 3D
85%
Fluicell AB
84%

Poietis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 27, 2018
SeedDec 17, 2015

Poietis Investors

Notable investors and investment history

Poietis investors
InvestorRounds
Nouvelle-Aquitaine Co-investissementCrowdfunding, Series A
Aquitaine Science TransfertSeed
Michelin DevelopmentSeed
WiSeedCrowdfunding, Series A, Seed
BpifranceCrowdfunding, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2018

    Raised $6.2M from government and other investors.

  • Dec 17, 2015

    $2.75M raised from Aquitaine Science Transfert and others.

Poietis Filings

Explore SEC and related filing metadata, where available.

Poietis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Poietis's valuation, stock price, and market status.

Is Poietis a public or private company?

Poietis is a private company.

What is the current stock price of Poietis?

Poietis is a private company with no public stock price. No recent secondary market data is available.

How much is Poietis worth (valuation)?

Valuation information for Poietis is not publicly available.

Can I buy Poietis stock?

Poietis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Poietis's last funding round?

Poietis's most recent funding round was Series A on March 27, 2018.

Who are the main investors in Poietis?

Key investors in Poietis include Bpifrance, Nouvelle-Aquitaine Co-investissement, Aquitaine Science Transfert, Michelin Development, WiSeed.

Will Poietis IPO soon?

No public IPO plans have been announced for Poietis.

How can I track Poietis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Poietis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPessac
Employee Range14
Year Founded2014
Last FundingMar 27, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?